Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer.
about
Optimal delivery of male breast cancer follow-up care: improving outcomesCognitive changes associated with ADT: a review of the literatureAndrogen receptor (AR) pathophysiological roles in androgen-related diseases in skin, bone/muscle, metabolic syndrome and neuron/immune systems: lessons learned from mice lacking AR in specific cellsAndrogens and stroke: good, bad or indifferent?A review of clinical effects associated with metabolic syndrome and exercise in prostate cancer patientsSalvage radiotherapy after radical prostatectomy: prediction of biochemical outcomesSalvage focal prostate cryoablation for locally recurrent prostate cancer after radiotherapy: initial results from the cryo on-line data registry.Conversion to monotherapy with luteinizing-hormone releasing hormone agonist or orchiectomy after reaching PSA nadir following maximal androgen blockade is able to prolong progression-free survival in patients with metastatic prostate cancer: A propRepeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrenceNo increased risk of dementia in patients receiving androgen deprivation therapy for prostate cancer: a 5-year follow-up study.Lifestyle guidelines for managing adverse effects on bone health and body composition in men treated with androgen deprivation therapy for prostate cancer: an updateAndrogen receptor signaling and mutations in prostate cancerPredictors of the rate of BMD loss in older men: findings from the CHAMP study.Early versus deferred androgen suppression therapy for patients with lymph node-positive prostate cancer after local therapy with curative intent: a systematic review.Predictors of fracture risk and bone mineral density in men with prostate cancer on androgen deprivation therapy.Quantifying the evidence for the risk of metabolic syndrome and its components following androgen deprivation therapy for prostate cancer: a meta-analysis.Low rates of bone mineral density measurement in Medicare beneficiaries with prostate cancer initiating androgen deprivation therapySurveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trialPSA Doubling Time Predicts for the Development of Distant Metastases for Patients Who Fail 3DCRT Or IMRT Using the Phoenix Definition.SBRT: An Opportunity to Improve Quality of Life for Oligometastatic Prostate Cancer.Long-term health outcomes in a British cohort of breast, colorectal and prostate cancer survivors: a database study.Risk of fracture in men with prostate cancer on androgen deprivation therapy: a population-based cohort study in New Zealand.Tolerance of Phellodendron amurense bark extract (Nexrutine®) in patients with human prostate cancerProstate cancer in elderly Croatian men: 5-HT genetic polymorphisms and the influence of androgen deprivation therapy on osteopenia--a pilot studyPatients receiving androgen deprivation therapy for prostate cancer have an increased risk of depressive disorderAndrogen-deprivation therapy alone versus combined with radiation therapy or chemotherapy for nonlocalized prostate cancer: a systematic review and meta-analysisNeuronal androgen receptor regulates insulin sensitivity via suppression of hypothalamic NF-κB-mediated PTP1B expression.Radiotherapy Combined With Androgen Deprivation for Bone Oligometastases After Primary Curative Radiotherapy for Prostate Cancer: A Retrospective StudyThe relation between age and androgen deprivation therapy use among men in the Medicare population receiving radiation therapy for prostate cancerTissue-selective regulation of androgen-responsive genesLong-term Toxicity of Cancer Treatment in Older PatientsAndrogen deprivation therapy through bilateral orchiectomy: increased metabolic risks.Type I Collagen Synthesis Marker Procollagen I N-Terminal Peptide (PINP) in Prostate Cancer Patients Undergoing Intermittent Androgen Suppression.Measurement of bone turnover in prostate cancer patients receiving intermittent androgen suppression therapy.Fitness outcomes from a randomised controlled trial of exercise training for men with prostate cancer: the ENGAGE study.Lower prostate cancer risk in Swedish men with the androgen receptor E213 A-allele.Loss of endothelial cell-specific molecule 1 promotes the tumorigenicity and metastasis of prostate cancer cells through regulation of the TIMP-1/MMP-9 expressionDifferential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails.Triptorelin embonate: a 6-month formulation for prostate cancer.Clinical exercise interventions in prostate cancer patients--a systematic review of randomized controlled trials.
P2860
Q26773195-BB38AA4D-821C-4C32-976E-9B7E31D31EAEQ26822767-81574D06-AA11-4F3D-8125-0BB9BAB21EFEQ27013914-04F6FED6-4BCB-4DEB-93A4-7C676707FB65Q27016156-6C9F67DA-9BC4-4EAF-9DF7-8C15A61B9090Q28076622-C583B876-5453-421D-908D-7D1276CF8C79Q28541306-04C82985-B5B3-4275-8828-DB5C884FEF2EQ30857429-8B797429-163B-4AC5-8794-8FE560B97031Q33750752-A65125C5-4DB2-4703-BA2C-250B92F83CDEQ33789117-F1FB8880-833D-4523-A3C2-478C7AD3FF5CQ33897252-FF06F365-D04D-4703-932E-F613ADAA71D8Q33900049-A614C682-DFB1-470F-A235-0E7E9038837BQ34425907-785BAA0E-292C-4D00-9BEF-BB7A245173AEQ34501378-9625B0CE-BD01-4EFF-BB8B-1241A306A537Q34627540-8D668419-5F06-4E42-A25A-8D5CA3FFC62EQ35149069-54E5399B-41C0-4992-8162-8CED205BDCB8Q35202889-826DF7CB-F610-4EF6-88ED-4E3064F7CC1DQ35206815-733652F5-181C-4713-8F1F-69FF12282B0DQ35253783-350BCB99-528E-4B45-A162-2C2051D762D4Q35400436-2A7EDAEF-A35C-4740-BA80-9F063420AE4DQ35569482-389215F4-9366-4327-A908-E871D10C0BDEQ35654258-EB461D6B-0C92-49FF-A079-DD9699D23E7AQ35829609-8975190F-C663-43AC-9F25-29A42B014F62Q35865808-852FA1E3-454D-4695-8E54-AF871ACFC508Q36041671-F3297B36-7E6B-4282-B6A3-753C365DBF7AQ36295478-2C30BE51-CA5B-467F-8E41-6A0604345F0FQ36530173-EAEE198E-66AC-4300-9649-E81737B137F7Q36560660-D59C5468-6D30-4DD0-B629-E5BE05169C8FQ36581142-74ED464E-0C66-4033-A212-CE49BD7FEA76Q36665817-99DE363B-7C38-43F7-9302-ACE1D5EDA46FQ36697482-EB17F3FF-42C8-412D-8666-851272648BB3Q36821673-CED0C4DE-1D10-4AA8-8F7D-08525205BEC6Q37085223-AFE59CD5-8160-44C6-B77B-90E1F580B0DAQ37137452-3588871D-6D9E-4BFB-A236-9F1440A1952CQ37283578-60B1E610-AC1F-407F-8C4F-AA088B0FA00DQ37389651-31872EBC-8ADF-45EF-A7F0-5EF0253D5688Q37666265-2D22750A-83E8-43A2-8967-4C6DAA6B1D0BQ37706719-4BF86E49-DFE2-4BBC-95A7-3E4646B258CBQ37741773-753D84F8-F1E7-4F5E-AB0B-883C5B0777FDQ37802378-D5774F8F-CF9C-4CA3-B9E1-EC8DB25834FEQ37944489-FF52B85E-423B-413A-BD10-36D6499DB5BD
P2860
Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Review of major adverse effect ...... y in men with prostate cancer.
@en
Review of major adverse effect ...... y in men with prostate cancer.
@nl
type
label
Review of major adverse effect ...... y in men with prostate cancer.
@en
Review of major adverse effect ...... y in men with prostate cancer.
@nl
prefLabel
Review of major adverse effect ...... y in men with prostate cancer.
@en
Review of major adverse effect ...... y in men with prostate cancer.
@nl
P2093
P2860
P356
P1433
P1476
Review of major adverse effect ...... y in men with prostate cancer.
@en
P2093
Lockwood G Taylor
Steven E Canfield
Xianglin L Du
P2860
P304
P356
10.1002/CNCR.24283
P407
P577
2009-06-01T00:00:00Z